Status:
ACTIVE_NOT_RECRUITING
Evaluating Cascade Communication Methods
Lead Sponsor:
University of Pennsylvania
Conditions:
BRCA1 Mutation
BRCA2 Mutation
Eligibility:
All Genders
18+ years
Brief Summary
Hereditary cancer programs face challenges with respect to effective communication of genetic test results within families and uptake of genetic testing by relatives. This study aims to determine if a...
Detailed Description
The identification of a single individual with a highly penetrant cancer susceptibility gene mutation can have far reaching implications for at-risk relatives in that other family members can engage i...
Eligibility Criteria
Inclusion
- 18 years of age and older
- Proband must be carrier of a high risk cancer predisposition gene
- Relative must be established relative of respective proband participant and deemed "at-risk" for familial gene mutation and eligible genetic testing candidate as per study team determination
- Participants must be able to understand and read English
- Participants must be able to provide informed verbal or written consent
Exclusion
- \<18 years of age
- Individuals who are mutation negative for high risk cancer predisposition genes
- Individuals who are carriers of a variant of uncertain significance in any gene
- Individuals who test positive for more than 1 high risk cancer predisposition gene
- Individuals who cannot speak and read English
- Individuals who do not have any at-risk relatives (eligible for familial gene mutation testing) as per study team determination
- Major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation
- Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff
- No available family members for cascade opportunity (adoption, estrangement, etc.)
Key Trial Info
Start Date :
February 19 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04428736
Start Date
February 19 2020
End Date
December 31 2025
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104